Search Results
Nivolumab + chemotherapy in previously untreated stage III or IV Hodgkin lymphoma
Nivolumab in Advanced Hodgkin’s Lymphoma | NEJM
ASCO 2023 Highlights on nivolumab in advanced stage classic Hodgkin Lymphoma: the SWOG S1826 study
Nivolumab-AVD improved PFS versus brentuximab vedotin-AVD in patients with advanced stage HL
The Rationale for Exploring Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma
Results of SWOG S1826 Study, showing Nivo-AVD better than BV-AVD in Hodgkin's Lymphoma patients
SWOG S1826: nivolumab+AVD vs brentuximab vedotin+AVD for advanced stage Hodgkin lymphoma
SWOG S1826: promising results with the combination of nivolumab-AVD in Hodgkin lymphoma
Long-Term Efficacy and Safety of Brentuximab Vedotin in Hodgkin Lymphoma Patients
Updates on the use of nivolumab in Hodgkin lymphoma & how this agent may impact treatment
Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 study
ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphoma
